Numerous sublingual immunotherapy studies have shown efficacy using a wide variety of dosing regimens. Despite a few grade III and one anaphylactic reaction due to a patient over-dose, there have been no fatal reactions resulting from sublingual immunotherapy treatment. Although safer than SCIT, SLIT is still immunotherapy. Special consideration should be given to what will ensure the highest l...

The English and non-English language literature on allergen immunotherapy was reviewed for studies simultaneously using 2 or more distinct allergen extracts in either subcutaneous or sublingual immunotherapy. Thirteen studies were identified, 11 using subcutaneous injections, 1 using sublingual administration, and 1 using both. In studies with adequate information, administration of 2 extracts ...

The house dust mite is a major cause of respiratory allergy worldwide. The management of mite allergy is based on avoidance measures, drug treatment, and allergen immunotherapy, but only allergen immunotherapy is able to modify the natural history of the disease. Injectable subcutaneous immunotherapy was introduced a century ago, while sublingual immunotherapy was proposed in the 1980s and emer...

sublingual allergen immunotherapy (slit) is considered to be safer and more convenient than subcutaneus immunotherapy. slit trials with house dust mites involving patients with allergic rhinitis (ar) and asthma reported discordant results. the aim of the study was to investigate the clinical efficacy and safety of slit with dermatophagoides pteronyssinus (d.pt) extract produced in serbia and pa...

BACKGROUND The aim of this study was to determine the safety of sublingual immunotherapy in pregnancy, which has not yet been reported. METHODS One hundred and fifty-five patients received sublingual immunotherapy with either house dust mite (D. farinae) or a mixture of up to five allergens during 185 pregnancies. Twenty-four patients received sublingual immunotherapy for the first time durin...

BACKGROUND/OBJECTIVES Sublingual immunotherapy was first described in 1986. Since then, its use has been increased as an alternative to subcutaneously administered immunotherapy in the treatment of allergic rhinitis. The most common side effects are of oropharyngeal and gastrointestinal in nature, for example, itching, swelling, irritation, ulceration of the oropharynx and nausea, abdominal pai...

BACKGROUND Immunotherapy has shown to be an effective treatment for the management of some IgE-mediated allergies. However, due to its long duration, a high number of patients withdraw from it before completion. OBJECTIVE Explore if allowing patients to select the route of immunotherapy, educational sessions and strict follow-up could improve treatment compliance. METHODS Patients consultin...